Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq 03:59:59 2024-03-01 pm EST 5-day change 1st Jan Change
95.03 USD +3.02% Intraday chart for Moderna, Inc. -1.48% -4.44%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Wall Street: a flurry of records, including that of the Nasdaq 'broad CF
Wall Street: a flurry of records, including that of the Nasdaq 'large'. CF
Novavax sees 2024 sales flat to lower, aims to pick up COVID vaccine market share RE
SolidWorld awarded EUR850,000 contract to supply 3D software AN
North American Morning Briefing : Stock Futures -2- DJ
Futures await lists in red AN
Wall Street: limited decline after 17 weeks of gains CF
Elis Completes Purchase of Dutch Flat Linen Provider Moderna Holding MT
Wall Street: limited decline after 17 weeks of gains CF
Moderna Slides After Downgrade From HSBC MT
Elis: completes acquisition of 100% of Moderna CF
How long will this bullish phase last? Our Logo
HSBC Downgrades Moderna to Reduce From Hold, Raises Price Target to $86 From $75 MT
Futures muted as traders buckle up for busy data week, inflation test RE
Futures muted as traders buckle up for inflation test RE
ANALYST RECOMMENDATIONS : AbbVie, Doordash, Eli Lilly, Moderna, Hiscox... Our Logo
Moderna's Cytomegalovirus Vaccine Opportunity Is Undervalued by Investors, UBS Says MT
Moderna Announces the Completion of Construction of Its Mrna Manufacturing Facility in Laval, Quebec CI
Canaccord Genuity Raises Moderna's Price Target to $91 From $82, Keeps Hold Rating MT
S&P 500, Dow surge to record closing highs RE
Health Care Up After Moderna Earnings -- Health Care Roundup DJ
Dow, S&P 500 Close at Record Highs as Nvidia, Moderna Rally MT
Dow, S&P 500 Close at Record Highs Amid Nvidia, Moderna Rally MT
S&P 500, Dow jump to record closes as Nvidia sparks AI frenzy RE
Sector Update: Health Care Stocks Gain Late Afternoon MT
Chart Moderna, Inc.
More charts
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
95.06 USD
Average target price
133.4 USD
Spread / Average Target
+40.28%
Consensus
  1. Stock
  2. Equities
  3. Stock Moderna, Inc. - Nasdaq
  4. News Moderna, Inc.
  5. Moderna's mRNA Patent Invalidated by European Patent Office
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW